

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-35. (canceled)

36. An monoclonal antibody or HAAH-binding fragment thereof, wherein said antibody binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the epitope binding specificity of said antibody comprises NPVEDS (residues 286-291 of SEQ ID NO:2).

37 – 38. (canceled)

39. A kit for detecting a tumor cell, comprising an antibody, or fragment thereof, which binds to HAAH SEQ ID NO:2, wherein the epitope binding specificity of said antibody comprises residues 286-291 of SEQ ID NO:2.

40. The kit of claim 39, further comprising a means for detecting binding of said antibody to said tumor cell.

41. The kit of claim 40, wherein said means is a detectable marker.

42. The kit of claim 41, wherein said detectable marker is a radioactive compound.

43. The kit of claim 41, wherein said detectable marker is Gd<sup>+++</sup> or Fe<sup>++</sup>.

44. A hybridoma cell line selected from the group consisting of hybridoma HA386A, ~~hybridoma HA15C7A, and hybridoma HA219B~~ hybridoma ATCC designation PTA 3383, hybridoma ATCC designation PTA 3384, and hybridoma ATCC designation PTA 3385.

45.-46 (canceled)

47. (newly added) The hybridoma cell line of claim 44, wherein said cell line is hybridoma ATCC designation PTA 3383.

48. (newly added) The hybridoma cell line of claim 44, wherein said cell line is hybridoma ATCC designation PTA 3384.

49. (newly added) The hybridoma cell line of claim 44, wherein said cell line is hybridoma ATCC designation PTA 3385.